Evoke shares surge following positive trial results


Evoke Pharma's (EVOK) shares soar 29% after a Phase IIb study shows that the company's intranasal delivery of metoclopramide is better at managing the symptoms of diabetic gastroparesis compared with the pill version.

Gastroparesis is a disorder in which the stomach takes too long to empty its contents. Metoclopramide is used to relieve feelings of nausea or vomiting.

Evoke plans to start a Phase III trial soon.

No new treatments for managing the symptoms of gastroparesis have received FDA approval since 1980. "There are very few drugs in clinical development for this debilitating diabetic complication," says Evoke CEO Dave Gonyer. (PR)

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs